Amanta Healthcare Limited

Amanta Healthcare Limited, established in December 1994 as Marck Parenterals (India) Limited, is a prominent Indian pharmaceutical company specializing in the development, manufacturing, and marketing of sterile liquid pharmaceutical products and medical devices. The company underwent a name change to Marck Biosciences Limited in November 2005 and subsequently to Amanta Healthcare Limited in June 2014. Headquartered in Ahmedabad, Gujarat, India, Amanta Healthcare operates with an authorized capital of ₹90.15 crore and a paid-up capital of ₹38.83 crore. The company employs approximately 522 individuals, reflecting its substantial workforce dedicated to its diverse operations. Amanta Healthcare is publicly listed on the National Stock Exchange of India under the ticker symbol AMANTA.

Amanta Healthcare's manufacturing facilities are strategically located in Kheda, Gujarat, India. These plants are designed to meet the stringent requirements of regulated markets, ensuring high-quality production standards. The facilities are equipped with specialized production lines for both Large Volume Parenterals (LVPs) and Small Volume Parenterals (SVPs), utilizing advanced technologies such as Aseptic Blow-Fill-Seal (ABFS) and Injection Stretch Blow Moulding (ISBM). The company's manufacturing capabilities encompass a wide range of products, including fluid therapy solutions, ophthalmic and respiratory care formulations, and medical devices.

Amanta Healthcare is led by a team of experienced professionals committed to driving the company's growth and innovation. Bhavesh Patel serves as the Chief Executive Officer (CEO), overseeing the company's strategic direction and operations. Paras Mehta holds the position of Chief Financial Officer (CFO), responsible for managing the company's financial strategies and performance. Anil Rathi serves as the Chief Operating Officer (COO), focusing on optimizing operational efficiency and effectiveness. Additionally, Nikhita Dipesh Dinodia acts as the Company Secretary, ensuring compliance with regulatory requirements and corporate governance standards.

Amanta Healthcare has established a significant presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's manufacturing facilities have been inspected and approved by various international regulatory authorities, such as the Therapeutic Goods Administration (TGA) of Australia and the Medicines Control Council (MCC) of South Africa. These approvals underscore Amanta Healthcare's commitment to adhering to global quality standards. The company's product portfolio, which includes fluid therapy solutions, ophthalmic and respiratory care formulations, and medical devices, aligns with the therapeutic needs of these markets, facilitating access and acceptance. Amanta Healthcare's strategic focus on innovation and quality has enabled it to navigate the complexities of these regulated markets effectively.

Amanta Healthcare has made strategic inroads into emerging markets, including Africa, Latin America, and Southeast Asia. The company's diverse product portfolio, encompassing fluid therapy solutions, ophthalmic and respiratory care formulations, and medical devices, positions it well to meet the healthcare needs of these regions. While specific details regarding WHO prequalification are not publicly disclosed, the company's adherence to international quality standards and regulatory approvals suggests a strong foundation for accessing and expanding in these emerging markets. Amanta Healthcare's focus on innovation and quality continues to drive its growth and presence in these regions.

Amanta Healthcare's geographic strategy demonstrates a balanced approach to market diversification and risk management. The company's significant export value of $6.4 million USD, derived from 165 shipments across two therapeutic categories, indicates a focused yet diversified product offering. The top five products, including Metronidazole and Salbutamol, contribute to a portfolio concentration of 100%, highlighting the company's strategic emphasis on these key products. This concentration suggests a deliberate focus on high-demand products, potentially enhancing operational efficiency and market penetration. However, the lack of a market leader status in any category indicates opportunities for further market share expansion. Amanta Healthcare's strategic direction appears to be geared towards consolidating its position in existing markets while exploring avenues for growth in new regions.

Amanta Healthcare's engagement with the U.S. Food and Drug Administration (FDA) is a critical aspect of its regulatory compliance and market access strategy. The company's manufacturing facilities have been inspected and approved by various international regulatory authorities, including the TGA of Australia and the MCC of South Africa. While specific details regarding FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly disclosed, the company's adherence to international quality standards and regulatory approvals suggests a strong foundation for potential FDA engagement. Amanta Healthcare's commitment to quality and regulatory compliance positions it favorably for future interactions with the FDA.

Amanta Healthcare's commitment to quality is evident in its manufacturing practices, which adhere to international standards. The company's facilities have been inspected and approved by various international regulatory authorities, including the TGA of Australia and the MCC of South Africa. While specific details regarding WHO prequalification and EU Good Manufacturing Practice (GMP) certificates are not publicly disclosed, the company's adherence to international quality standards and regulatory approvals suggests a strong foundation for compliance with WHO and EU GMP requirements. Amanta Healthcare's focus on innovation and quality continues to drive its growth and presence in regulated markets.

Amanta Healthcare operates under the regulatory framework of the Central Drugs Standard Control Organisation (CDSCO) in India. The company's manufacturing facilities are designed to meet the stringent requirements of regulated markets, ensuring high-quality production standards. Specific details regarding CDSCO manufacturing licenses, state drug controller approvals, and export No Objection Certificates (NOCs) are not publicly disclosed. However, the company's adherence to international quality standards and regulatory approvals suggests compliance with Indian regulatory requirements. Amanta Healthcare's commitment to quality and regulatory compliance positions it favorably in both domestic and international markets.

As of March 2026, there are no publicly available records indicating any Form 483 observations, warning letters, or import alerts issued to Amanta Healthcare by regulatory authorities. The company's adherence to international quality standards and regulatory approvals suggests a strong compliance record. Amanta Healthcare's commitment to quality and regulatory compliance continues to support its operations and market presence.

Amanta Healthcare operates in a competitive landscape characterized by numerous pharmaceutical companies offering similar products. While specific market share data for Amanta Healthcare's overlapping categories is not publicly disclosed, the company's focus on sterile liquid products and medical devices positions it in direct competition with both domestic and international players. The company's strategic emphasis on innovation, quality, and regulatory compliance provides a competitive edge in the market. Amanta Healthcare's diverse product portfolio and manufacturing capabilities enable it to cater to a wide range of therapeutic segments, enhancing its competitiveness.

Amanta Healthcare's key differentiators include its diverse product portfolio, encompassing fluid therapy solutions, ophthalmic and respiratory care formulations, and medical devices. The company's manufacturing facilities utilize advanced technologies such as Aseptic Blow-Fill-Seal (ABFS) and Injection Stretch Blow Moulding (ISBM), ensuring high-quality production standards. Additionally, Amanta Healthcare's commitment to innovation and quality positions it as a versatile contract manufacturing partner, capable of developing customized solutions for its clients.

Amanta Healthcare's current strategic direction focuses on expanding its presence in both domestic and international markets by leveraging its diverse product portfolio and manufacturing capabilities. The company's emphasis on innovation and quality supports its growth objectives and enhances its competitive position. Future outlooks suggest a continued focus on regulatory compliance, market diversification, and strategic partnerships to drive long-term value creation and market expansion.

Amanta Healthcare's track record as a supplier is characterized by its adherence to international quality standards and regulatory approvals. The company's export volume and consistency, as evidenced by its total export value of $6.4 million USD from 165 shipments, reflect its reliability and commitment to meeting market demands. Amanta Healthcare's focus on innovation and quality continues to drive its growth and presence in both domestic and international markets.

Importers should verify the following certifications when engaging with Amanta Healthcare: